Biolegend, 652153, Ultra-LEAF™ Purified anti-human CD269 (BCMA) Antibody, 100μg

Human TNFRSF17 (B cell maturation antigen, BCMA) is a type I attached membrane protein of 184 amino acids, with a conserved motif of six cysteines in the N-terminal end, consistent with the formation of a cysteine repeat motif found in the extracellular domain of TNFRs. Overexpression of TNFRSF17 in 293 cells activates NF-kappa B, Elk-1, c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase, after its association with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3. Soluble forms of TACI (TNFRSF13B) and TNFRSF17 bind to BAFF (TNFSFL13B) and APRIL (TNFSFL13A). TNFRSF17-APRIL interaction has higher affinity than TNFRSF17-BAFF interaction. Analysis of TNFRSF17 knockout mice (TNFRSF17−/−) demonstrates no differences in the steady-state frequencies or composition of peripheral B cell subsets (immature, marginal zone, follicular, B1). PBMCs from mice with Sjogren’s-like syndrome demonstrates upregulated TNFRSF17 expression. TNFRSF17 is also increased in patients with Sjogren’s syndrome, rheumatoid arthritis, and on B cells from SLE patients. Patients with multiple myeloma show elevated levels of TNFRSF17 in serum, and it correlated with the proportion of plasma cells in bone marrow biopsies and clinical status. Serum TNFRSF17 levels in considered a novel biomarker to predict outcomes for multiple myeloma patients.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Recombinant Human TNFRSF17-Fc Chimera
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/μg of the protein (< 0.001 ng/μg of the protein) as determined by the LAL test
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Block - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by blocking the binding of 0.05 µg/mL biotinylated human TNFRSF17-Fc chimera (Cat. No. 796404) to immobilized 0.3 µg/mL recombinant human APRIL / TNFSF13. ND50 range: 0.05 - 0.3 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_3662332 (BioLegend Cat. No. 652153) AB_3662332 (BioLegend Cat. No. 652154)
Structure: Homodimer
Distribution: Resting and activated B cells, malignant B lymphocytes, plasma cells
Function: Maintains the peripheral B cell population and survival of long-lived bone marrow plasma cells. Soluble BCMA acts as a decoy receptor for APRIL. TNFRSF17 mRNA is stimulated by IL-4 and IL-6 in murine B cells.
Interaction: Monocytes, macrophages, T cells, and dendritic cells
Ligand/Receptor: TNFSF13 (APRIL), TNFSF (BAFF)
Cell Type: B cells, Plasma cells
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: Madry C, et al. 1998. Int Immunol. 10:1693-702. Hatzoglou A, et al. 2000. J Immunol. 165:1322-30. Rennert P, et al. 2000. J Exp Med. 192:1677-84. Wallweber HJ, et al. 2004. J Mol Biol. 343:283-90. O'Connor BP, et al. 2004. J Exp Med. 199:91-8. Kim J, et al. 2011. Autoimmunity. 44:69-81. Coqueri CM, and Erickson LD. 2012. Crit Rev Immunol. 32:287-305. Laurent SA, et al. 2015. Nature Commun. 6:7333. Ghermezi M, et al. 2017. Hematologica. 102:785-795.
Gene ID: 608
UniProt: View information about CD269 on UniProt.org
Clone: A21044E
Regulatory Status: RUO
Other Names: B cell maturation antigen (BCMA), tumor necrosis factor receptor superfamily member 17, CD269
Isotype: Mouse IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.